Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.50
Bid: 1,772.00
Ask: 1,772.50
Change: 12.50 (0.71%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

27 Nov 2018 15:25

RNS Number : 6693I
GlaxoSmithKline PLC
27 November 2018
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

Previous balance: 33,863*

Restated balance: -27,669

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

575,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

547,331

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

*Due to clerical error the opening balance has been restated.

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

Previous balance: 2,693,951*

Restated balance: 2,755,483

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

532,131

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2,223,352

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

*Due to clerical error the opening balance has been restated.

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - ADS

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

7,909,994

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

573,898

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

7,336,096

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

Date: 27 November 2018

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2018

To:

31 October 2018

Balance of unallotted securities under scheme(s) from previous return:

827,306

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

5,000,000

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

154,683

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

5,672,623

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRZMMZMKNZGRZM
Date   Source Headline
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
2nd May 20233:00 pmRNSTotal Voting Rights
28th Apr 20235:01 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amRNSGSK RSV OA vaccine gains positive EMA CHMP opinion
26th Apr 20237:00 amRNS1st Quarter Results
25th Apr 20237:00 amRNSEMA validates Jemperli filing for new indication
20th Apr 20233:30 pmRNSDirector/PDMR Shareholding
19th Apr 20233:30 pmRNSDirector/PDMR Shareholding
18th Apr 20237:00 amRNSGSK reaches agreement to acquire BELLUS Health Inc
17th Apr 20233:30 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSGepotidacin positive phase III data
3rd Apr 20233:00 pmRNSTotal Voting Rights
28th Mar 20237:00 amRNSPositive phase III RUBY results for Jemperli
27th Mar 20231:00 pmRNSPublication of 2023 AGM Notice
24th Mar 20239:59 amRNSStatement: Zantac (ranitidine) litigation
21st Mar 20233:30 pmRNSDirector/PDMR Shareholding
20th Mar 20233:30 pmRNSDirector/PDMR Shareholding
14th Mar 20237:05 amRNSPositive phase III results for MenABCWY vaccine
14th Mar 20237:00 amRNSNucala NDA accepted for review in China
13th Mar 20233:30 pmRNSDirector/PDMR Shareholding
10th Mar 20234:26 pmRNSGSK Annual Report 2022 on Form 20-F
10th Mar 202310:36 amRNSGSK publishes Annual Report 2022
2nd Mar 20237:00 amRNSFDA Ad Com votes to support GSK RSV OA vaccine
1st Mar 20233:00 pmRNSTotal Voting Rights
27th Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20233:30 pmRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSViiV Healthcare announces Cabenuva positive data
22nd Feb 20233:30 pmRNSDirector/PDMR Shareholding
16th Feb 20237:00 amRNSNEJM publishes GSK RSV OA vaccine candidate trial
15th Feb 20234:04 pmRNSDirector/PDMR Shareholding
15th Feb 20234:00 pmRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
14th Feb 20237:00 amRNSDirector/PDMR Shareholding
13th Feb 20235:35 pmRNSEMTN Notes repurchase results
10th Feb 20233:30 pmRNSDirector/PDMR Shareholding
10th Feb 20237:05 amRNSJemperli full FDA approval following GARNET trial
10th Feb 20237:00 amRNSJemperli FDA ODAC positive outcome
2nd Feb 20237:00 amRNSDaprodustat approved by US FDA for anaemia of CKD
1st Feb 20233:30 pmRNSDirector/PDMR Shareholding
1st Feb 20233:00 pmRNSTotal Voting Rights
1st Feb 20237:05 amRNSBenlysta granted Orphan Drug Designation by US FDA
1st Feb 20237:00 amRNSFinal Results
18th Jan 20233:30 pmRNSDirector/PDMR Shareholding
17th Jan 20233:30 pmRNSDirector/PDMR Shareholding
16th Jan 20233:30 pmRNSDirector/PDMR Shareholding
13th Jan 20233:30 pmRNSDirector/PDMR Shareholding
12th Jan 20233:30 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.